1619901-87-9

Usage

Uses

Used in Pharmaceutical Industry:
(2S)-1-(11bS)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl-1,2,3,4-tetrahydro-2-methylquinoline, 99% e.e. is used as a chiral building block for the synthesis of pharmaceutical compounds. The specific enantiomeric form may confer unique biological activities, making it a valuable component in the development of new drugs with targeted therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, (2S)-1-(11bS)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl-1,2,3,4-tetrahydro-2-methylquinoline, 99% e.e. may be utilized as a key intermediate in the production of enantioselective pesticides or herbicides. The enantiomeric purity ensures that the desired biological activity is achieved without the potential side effects of the opposite enantiomer.
Further Research and Development:
Due to the complex structure and high enantiomeric purity of (2S)-1-(11bS)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl-1,2,3,4-tetrahydro-2-methylquinoline, 99% e.e., further research is necessary to explore its full potential in various applications. This may include studies on its interaction with biological targets, optimization of synthesis methods, and evaluation of its safety and efficacy in different contexts.

Upstream product

• 18531-94-7 (R)-1,1'-Bi-2-naphthol 
• 1780-19-4 (R)-1,2,3,4-tetrahydroquinaldine 
• 18531-99-2 (S)-[1,1']-binaphthalenyl-2,2'-diol 
• 604-53-5 (R)-(+)-2,2'bis(diphenylphosphino)-1,1'-binaphthalene 

Relevant academic research and scientific papers

Palladium-Catalyzed Cascade to Benzoxepins by Using Vinyl-Substituted Donor–Acceptor Cyclopropanes

A palladium-catalyzed intermolecular cascade (4+3) cyclocondensation of salicylaldehydes and vinylcyclopropanes is reported. A key feature of the reaction is the use of a phosphonate group as an acceptor moiety on the cyclopropane, exploiting its propensity to undergo olefination with aldehydes. Subsequent O-allylation enabled the formation of a range of substituted benzoxepinsWith a novel chiral ligand, the products were obtained in generally good yield and with reasonable enantioselectivity.

benzimidazole chiral heterocyclic compound as well as preparation method and application thereof

The invention discloses a benzimidazole chiral heterocyclic compound as well as a preparation method and application thereof. The structure formula of the benzimidazole chiral heterocyclic compound isshown in formula I, formula II or formula III in the description. The benzimidazole chiral heterocyclic compound is prepared by treating an iridium complex which is prepared through a metal iridium compound and a phosphoramidite ligand as a catalyst, performing intra-molecular allyl amination on allyl substrate, and then synthesizing with high efficiency and high enantioselectivity. The method has the advantages of being high in catalytic reaction activity, mild in reaction conditions, high in enantioselectivity, wide in substrate applicable scope, and environmentally friendly; the primary in-vitro enzyme inhibition activity test shows that the compound is high in alpha-glucosidase inhibiting activity and can be used as an alpha-glucosidase inhibiting agent, and the compound can also be used as a further modified drug intermediate; the compound has a potential application value in preventing or treating II-diabetes, obesity and complication medicines thereof and pilot compounds thereof.

Iridium-catalyzed allylic alkylation reaction with N-aryl phosphoramidite ligands: Scope and mechanistic studies

A series of N-aryl phosphoramidite ligands has been synthesized and applied to iridium-catalyzed allylic alkylation reactions, offering high regio- and enantioselectivities for a wide variety of substrates. These ligands feature the synthetic convenience and good tolerance of the ortho-substituted cinnamyl carbonates. Mechanistic studies, including DFT calculations and X-ray crystallographic analyses of the (π-allyl)-Ir complexes, reveal that the active iridacycle is formed via C(sp2)-H bond activation.